Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Express Scripts
Baxter
Harvard Business School

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: RE44733

See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE44733 protect, and when does it expire?

Patent RE44733 protects BRIDION and is included in one NDA.

This patent has forty-two patent family members in thirty countries.

Summary for Patent: RE44733
Title:6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p--; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block. ##STR00001##
Inventor(s): Zhang; Mingiang (Montreal, CA), Palin; Ronald (Banton, GB), Bennett; Jonathan (Edinburgh, GB)
Assignee: Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:13/432,742
Patent Claim Types:
see list of patent claims
Compound; Composition; Device; Use;

Drugs Protected by US Patent RE44733

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No   Start Trial   Start Trial Y Y REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK   Start Trial
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes   Start Trial   Start Trial Y Y REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE44733

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99309558Nov 29, 1999
PCT Information
PCT FiledNovember 23, 2000PCT Application Number:PCT/EP00/11789
PCT Publication Date:June 07, 2001PCT Publication Number: WO01/40316

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
McKinsey
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.